Clinical Utility of Serum Human Epidermal Growth Factor Receptor Type 2 Testing as a Marker of Therapeutic Response In Tissue HER2-Positive Breast Cancer Patients
Seiichi Mokuyasu and Yasuhiro Suzuki
Human Epidermal growth factor Receptor type 2 (HER2) is over expressed in 20.0-30.0% of breast cancers and is currently evaluated histopathologically. Immunohistochemistry and fluorescence in situ hybridization require invasive enucleation of the tumor tissue and may be affected by heterogeneity.
Muhammad A Khattak and Elin Gray
Uveal Melanoma is a rare tumour that displays different clinical behavior and molecular features compared with cutaneous melanoma. It is generally resistant to systemic therapy and there is no current standard effective therapy to treat patients with advanced disease.
short review article
BH Behzad Niakan
Once a malignant growth grows past a certain size immune tolerance rather than immune sensitization occurs possibly due to the slow tumor growth. As the malignant grows larger some branches of the immune system (adoptive immunity) become protective of it, while other branches of the immune system oppose its growth.
The Omission of Axillary Lymph Node Dissection in Sentinel Node-Positive Breast Cancer Patients Requires Careful Consideration
Hiroko Nogi, Takashi Kazama, Rei Mimoto, Yoshimi Imawari, Makiko Kamio, Hisashi Shioya, Yasuo Toriumi, Ken Uchida, Masafumi Suzuki and Hiroshi Takeyama
Sentinel Node Biopsy (SNB) is used to accurately assess axillary lymph node status in patients with node-negative breast cancer. The purpose of this study was to assess the association between non-sentinel node (SN) metastasis and clinicopathological findings in patients with one or two SN-positive breast cancer.
Gonzalez-Montoya Marcela, Cano-Sampedro Eden and Mora-Escobedo Rosalva
Food proteins are a source of nutraceutical and bioactive peptides that promote health and prevent diseases. Legume seed proteins have been widely studied to produce peptides (protein fragments) with a diversity of biological activities.
Sankar Arumugam, Aitang Xing, Tony Young, David Thwaites and Lois Holloway
Ten each of prostate and head and neck (H&N) VMAT plans were considered for this study. Three types of errors were introduced into the original plans: gantry angle independent and dependent MLC errors, and gantry angle dependent dose error. The percentage difference in PTV-D95 between TPS and 3DVH was compared for no-error and error introduced plans.
For men with metastatic breast adenocarcinoma standard therapies typically involve the same therapies used for woman. Recently the FDA approved the aromatase inhibitor letrozole combined with the inhibitor of cyclin dependent kinase 4/6 (CDK4/6) palbociclib as first line therapy for women with metastatic breast cancer. Here we report a first case of a man with metastatic breast cancer whose tumor responded to palbociclib and letrozole. This combination might be effective for other men with metastatic breast cancer as well.
Three-Dimensional Ultrasound: Is it Useful for Decision Making in the Management of Rectal Cancer? Is 3D Ultrasound Useful in Rectal Tumor?
Sthela M Murad-Regadas, Romulo M Almeida, Rosilma G Lima Barreto, Doryane MR Lima, Francisco Sergio Pinheiro Regadas, Lusmar Veras Rodrigues, Francisco Coracy C Monteiro, Paulo G Oliveira, Joao Batista Barreto and Univaldo Etsuo Sagae
Consecutive patients treated for rectal cancer or adenomas in 4 colorectal centers in Brazil were included. Patients with early-stage rectal cancer identified by 3D-US were assigned to receive resection only, and those with a later stage were assigned to receive CRT. A second 3D-US was performed after CRT to detect the presence of residual tumor and metastatic lymph nodes or complete response.
Original Research Article
Magnetic Resonance Imaging Targeted Biopsies alone are not Sufficient for Detection of Clinically Significant Prostate Cancer - A Systematic Review and Meta-Analysis
Cayce B Nawaf, Nathanial T Ondeck, Laura A Skrip, Rollin K Say, John M Gunselman, Jamil Syed, Peter G Schulam and Preston C Sprenkle
Magnetic resonance imaging targeted biopsies (MRI-Tbx) has the potential to detect significant prostate cancer with a small number of cores; however, there are concerns that some clinically significant (CS) cancers may not be visible on MRI or identified with targeted biopsies alone.